CCA
ONCT

Column Capital Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Column Capital Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$435 Hold
73
– – ﹤0.01% 769
2023
Q2 		$500 Hold
73
– – ﹤0.01% 776
2023
Q1 		$1.14K Hold
73
– – ﹤0.01% 762
2022
Q4 		$1.45K Buy
+73
New +$1.45K ﹤0.01% 727

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $786M AUM 19.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Column Capital Advisors's ONCT Position: Q3 2023 in Review

Column Capital Advisors held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q3 2023 at 73 shares worth $435. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Column Capital Advisors first reported a position in ONCT in Q4 2022 and has held it in 4 quarters since. The position peaked at $1.45K in Q4 2022. 50 funds tracked by Wall St. Rank hold ONCT as of Q3 2023.

  • Column Capital Advisors held 73 shares of Oncternal Therapeutics, Inc. Common Stock worth $435 as of Q3 2023.
  • Column Capital Advisors left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q3 2023.
  • Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #769 holding.
  • Column Capital Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2022 and has held it in 4 quarters since.
  • Column Capital Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.45K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.